This is good info, It kind of shows why GILD might not be jumping all over CYDY. As much as we have a better product closer to FDA approval, it might not fit into the heavily invested product pipeline already going. How would GILD tell their share holders the millions invested in one drug has been shelved and billions have been used to buy out an alternative? It very much creates an opportunity for some other BP looking to take some of GILD's market share. They now know what GILD is working on and how Leronlimab compares scientifically and financially.